Market Analysis Report Bone Cancer Market 2019 - 2023 | Página 2

Bone cancer is one the types of cancer in which the tissues of bone start growing in uncontrollable
manner. This growth can be benign or malignant. In most of the cases, the bone cancer is a result from
other cancers. The growth of Bone Cancer Market anticipated to be driven by various factors, such as,
R&D practices running across the globe, rising awareness amongst the population for bone cancer and
other bone diseases, increasing medical infrastructure and technological advancements. Owing to R&D
practices, a number of drugs and formulations are under pipeline studies and are expected to enter in
the market during forecast period.
Bone Cancer Market Covers the Table of Contents With Segments, Key Players And Region. Based on
Product Type, Bone Cancer Market is sub segmented into Chemotherapy and Targeted Therapy. On the
Basis of Application, Market is sub segmented into Primary Bone Cancer and Secondary Bone Cancer.
Major Players profiled in the Bone Cancer Market report incorporate: Amgen, Baxter, Bayer, Hikma
Pharmaceuticals, Johnson&Johnson, Recordati Group, Novartis AG, Pfizer, Takeda Pharmaceutical
Industry News:
Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today announced that the U.S. Food and
Drug Administration (FDA) has approved EVENITY™ (romosozumab-aqqg) for the treatment of
osteoporosis in postmenopausal women at high risk for fracture. EVENITY is the first and only bone
builder with a unique dual effect that both increases bone formation and to a lesser extent reduces
bone resorption (or bone loss) to rapidly reduce the risk of fracture. A full course of EVENITY therapy is
12 monthly doses administered by a healthcare provider.2 Since osteoporosis is a chronic disease,
continued therapy with an anti-resorptive agent should be considered once EVENITY therapy is
completed.
The FDA based its approval of EVENITY on the results of two Phase 3 studies. In the placebo-controlled
FRAME study, treatment with EVENITY resulted in a significant reduction of new vertebral (spine)
fracture at 12 months compared to placebo. This significant reduction in fracture risk persisted through
the second year in women who received EVENITY during the first year and transitioned to denosumab
compared to those who transitioned from placebo to denosumab. In addition, EVENITY significantly
increased bone mineral density (BMD) at the lumbar spine, total hip and femoral neck compared to
placebo at 12 months.
Request a Discount on standard prices of this premium report @
https://www.businessindustryreports.com/check-discount/164089 .
Region segment: This report is segmented into several key regions, with sales, revenue, market share
(%) and growth Rate (%) of Bone Cancer in these regions, from 2014 to 2023 (forecast), covering: North
America, Europe, Asia Pacific, Middle East & Africa and South America.
Significant points in table of contents: Market Definition, Market Overview, Business Introduction,
Segmentation (Region Level), Segmentation (Type Level), Segmentation (Industry Level), Segmentation